Ozempic vs Wegovy 2026: What's the Difference?

See if you qualify in 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on the 3-month and 6-month plans (full refund on 3-month and 6-month plans) · cancel anytime

Ozempic vs Wegovy: At a Glance

	Ozempic	Wegovy
Active ingredient	Semaglutide	Semaglutide
Manufacturer	Novo Nordisk	Novo Nordisk
FDA-approved for	Type 2 diabetes; cardiovascular risk reduction in T2D	Chronic weight management; cardiovascular risk reduction in obesity
Max dose (injectable)	2.0 mg / week	2.4 mg / week
Route	Once-weekly injection	Once-weekly injection (pill also available)
Typical use	Blood-sugar control (primarily)	Weight loss / weight management
Insurance coverage	Broadly covered for T2D	Frequently excluded; prior auth often required
Self-pay cost (est., Jun 2026)	List price ~$900+/mo; savings card may apply	List price ~$1,349/mo; NovoCare ~$349/mo for eligible patients

Drug facts from FDA-approved prescribing information; prices from publicly available manufacturer savings programs and pharmacy benefit data as of June 2026. Prices change frequently — verify with your pharmacy or insurer.

Same molecule, different label: why two brand names?

The confusion here is understandable. Novo Nordisk ran separate clinical programs for semaglutide — one for type 2 diabetes (which became Ozempic) and one for weight management (which became Wegovy). Each received its own FDA approval, its own prescribing information, and its own dosing regimen. The molecule underneath is identical; the approved application differs.

Ozempic is indicated for glycemic control in adults with type 2 diabetes, with a secondary approval for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It titrates up to 2.0 mg per week.

Wegovy is indicated for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition (such as high blood pressure, high cholesterol, or type 2 diabetes). Its maintenance dose is 2.4 mg per week, slightly higher than Ozempic's ceiling. In 2024 the FDA also approved Wegovy for reducing the risk of serious cardiovascular events in adults with obesity or overweight and established cardiovascular disease — making it the first weight-loss medication with that cardiovascular indication.

What does the higher dose mean for weight loss?

The 2.4 mg ceiling was chosen for weight management because higher doses of semaglutide produced greater average weight loss in the STEP clinical trial program — up to a point where tolerability stabilizes. In the pivotal STEP-1 trial (Wilding et al., NEJM 2021), adults with obesity who were treated with the FDA-approved branded drug Wegovy (semaglutide 2.4 mg/week) lost an average of approximately 14.9% of body weight over 68 weeks. These are outcomes from a placebo-controlled trial of the branded product; individual results vary, and these trial results describe Wegovy as studied — not any other formulation of semaglutide.

Ozempic's 2.0 mg dose was not separately optimized for weight management. Studies have observed weight-loss effects at Ozempic doses, but Wegovy at 2.4 mg is the version studied and approved specifically for that purpose.

One practical takeaway: if a clinician determines that semaglutide-based weight management is appropriate for you, the on-label choice is Wegovy, not Ozempic — even though they are the same molecule.

Wegovy's cardiovascular indication: what the SELECT trial showed

In 2023, the SELECT trial (Lincoff et al., NEJM 2023) reported that semaglutide 2.4 mg — the active ingredient in Wegovy — reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by approximately 20% compared with placebo in adults who had established cardiovascular disease and obesity, but did not have diabetes. This was a landmark result because it was the first major cardiovascular outcomes trial for a weight-loss medication in non-diabetic adults with obesity.

Based on SELECT, the FDA approved an expanded indication for Wegovy in 2024: reducing the risk of serious cardiovascular events in adults with obesity or overweight and established CV disease. This cardiovascular benefit is specific to the Wegovy label and its 2.4 mg dose, not to Ozempic's approved uses. If you have obesity and known heart disease, your cardiologist or primary care provider may consider Wegovy as part of a cardiovascular risk-reduction plan — talk to your clinician about what applies to your situation.

How much does Ozempic vs Wegovy cost in 2026?

Cost is often the deciding factor for people weighing their options, and it varies considerably depending on insurance status:

Without insurance (self-pay)

Both medications carry high list prices at retail pharmacies. Wegovy's list price is approximately $1,349/month as of June 2026; Ozempic's is approximately $900+ per month, though both fluctuate. Most people do not pay list price.

Novo Nordisk's NovoCare savings program brings Wegovy's out-of-pocket cost to approximately $349/month for eligible self-pay patients (as of June 2026; eligibility and pricing are set by Novo Nordisk and subject to change — verify current terms directly with NovoCare). Ozempic has a separate savings-card program; eligibility and amounts vary.

With insurance

Ozempic has a significant coverage advantage for its approved indication: it is widely covered by commercial insurance and Medicare Part D plans for type 2 diabetes management. Copays with coverage can be much lower than self-pay rates.

Wegovy faces a different reality. Many commercial plans and Medicare Part D have historically excluded coverage for weight-management medications, or required burdensome prior authorization. Coverage has been improving — some employers now explicitly cover it — but the gap between Ozempic (for diabetes) and Wegovy (for weight management) remains wide at the plan level. If your employer or insurer covers anti-obesity medications, Wegovy may be accessible at a lower cost. For more on coverage strategy, see our guide to insurance and GLP-1 medications and how to get GLP-1 coverage.

HSA/FSA reimbursement

Compounded GLP-1 medications (when prescribed by a physician) may be eligible for FSA/HSA reimbursement under IRC §213(d), with a receipt and, in some cases, a letter of medical necessity. This depends on your specific plan — confirm eligibility with your plan administrator before assuming reimbursement is available.

For a full 2026 cost breakdown across all GLP-1 options, see our GLP-1 cost guide, or the individual price pages for Wegovy cost without insurance and Ozempic cost without insurance. Live pricing data across telehealth providers is also maintained in the Nouri GLP-1 Telehealth Pricing dataset.

Is Ozempic ever prescribed off-label for weight loss?

Yes, it happens. Because Ozempic and Wegovy are the same molecule, and because Ozempic is widely covered for diabetes, some clinicians prescribe Ozempic off-label for weight management — especially when Wegovy is not covered by a patient's insurance. This practice is legal and occurs, but it carries trade-offs:

• Lower maximum dose: Ozempic's highest approved dose (2.0 mg/week) is below Wegovy's weight-management ceiling (2.4 mg/week).
• Insurance friction: off-label prescriptions may be denied coverage, and the prescriber may face additional paperwork.
• On-label choice: Wegovy is the approved weight-loss product. A clinician prescribing Ozempic off-label for weight management is working around coverage gaps, not following the standard of care for this indication.

Whether Ozempic or Wegovy is appropriate — and whether either is covered — is a clinical and insurance question your provider navigates with you. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provides an overview of prescription medications approved to treat overweight and obesity.

The new oral semaglutide option (2025)

In December 2025 the FDA approved an oral semaglutide tablet at 25 mg for chronic weight management — a separate Wegovy product in pill form. This is distinct from Rybelsus® (the older oral semaglutide approved for type 2 diabetes at 7–14 mg) and from injectable Ozempic. All three contain semaglutide; all three are different FDA-approved products.

The oral Wegovy option matters if injections are a barrier. Clinical trial data on the oral form showed approximately 16.6% average weight loss — results from the branded oral medication in its pivotal trial; individual results vary, and this number describes the studied drug, not any compounded product. If you prefer a pill over a weekly injection, ask your clinician whether the oral Wegovy form is appropriate and covered under your plan.

For a deeper comparison of the injection and pill formats, see oral vs injectable semaglutide.

How does Ozempic vs Wegovy compare to tirzepatide options?

If you are weighing all GLP-1 choices, tirzepatide (Mounjaro® for diabetes, Zepbound® for weight management) is a separate molecule — a dual GIP/GLP-1 receptor agonist from Eli Lilly — that has shown higher average weight loss in some head-to-head data. The SURMOUNT-5 trial (NEJM 2025) compared tirzepatide directly against semaglutide in adults with obesity; those results describe the FDA-approved branded drugs studied in that trial.

The choice between semaglutide-based and tirzepatide-based options involves efficacy, tolerability, cost, coverage, and clinical appropriateness — all factors a clinician weighs. For a detailed breakdown, see our tirzepatide vs semaglutide comparison, and for cost specifics, our Zepbound vs Ozempic guide.

Where compounded semaglutide fits

Some people who cannot access or afford brand-name Wegovy or Ozempic explore compounded semaglutide through telehealth providers. It is important to understand the legal and clinical distinctions before doing so:

• Compounded semaglutide is not FDA-approved and is not therapeutically equivalent to Wegovy or Ozempic. It has not been studied in the STEP, SELECT, or other major clinical trials. Those trial results belong to the FDA-approved branded products.
• Compounding is legal for individual patients when prescribed by a licensed physician who determines it is clinically appropriate — it is not a generic or substitute for the branded drugs.
• Cost is the primary practical difference. Compounded semaglutide from telehealth providers generally costs substantially less than brand self-pay pricing; the Nouri GLP-1 Telehealth Pricing dataset tracks current rates across providers.
• The FDA has raised concerns about unapproved compounded GLP-1 products and the accuracy of their labeling; patients should work only with providers using state-licensed 503A compounding pharmacies and U.S.-licensed prescribing physicians.

For a full factual comparison of compounded vs brand options on price and legal status, see compounded semaglutide vs Wegovy and brand-name vs compounded GLP-1.

Where the Nouri program fits

If you and a licensed clinician decide a GLP-1 medication is right for you, the Nouri program offers compounded semaglutide or compounded tirzepatide as part of one complete membership — the medication (when prescribed) plus a personalized nutrition plan, a fitness plan, and ongoing clinician access, all at one price. No separate plan fee; any dose, same price.

Pricing (as of June 2026): compounded semaglutide starting at $120/month on the six-month plan ($720 billed every six months); compounded tirzepatide starting at $175/month on the six-month plan ($1,050 billed every six months). Shorter-term plans are available at higher monthly rates — see joinnouri.com/becoming for the full pricing table.

Medication is prepared by state-licensed 503A compounding pharmacies — Jungle Jim's Pharmacy (Fairfield, OH) and VialsRX — and ships free and discreetly in all 50 states. Nouri is LegitScript-certified. Your enrollment is backed by the Nouri Promise: a full refund in your first 30 days, available on the 3-month and 6-month plans.

Important: Nouri's compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as — and are not therapeutically equivalent to — Wegovy, Ozempic, Zepbound, or Mounjaro. Medication is prescribed only if a licensed physician determines it is clinically appropriate after reviewing your intake; not all applicants qualify. Published trial results referenced in this article are from FDA-approved branded drugs, not from Nouri's compounded products.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on the 3-month and 6-month plans (full refund on 3-month and 6-month plans) · cancel anytime

Related comparisons

• Tirzepatide vs Semaglutide: which GLP-1 is right for you?
• Zepbound vs Ozempic: differences, cost, and coverage
• Oral vs Injectable Semaglutide (2025)
• Compounded Semaglutide vs Wegovy: price, access, and legal status
• Brand-Name vs Compounded GLP-1: what to know
• GLP-1 cost guide 2026 (all options)

Frequently asked questions

Are Ozempic and Wegovy the same thing?

They contain the same drug — semaglutide, made by Novo Nordisk — but are FDA-approved for different uses: Ozempic for type 2 diabetes (max 2.0 mg/week), Wegovy for chronic weight management (max 2.4 mg/week injectable).

Which is better for weight loss, Ozempic or Wegovy?

Wegovy is the FDA-approved weight-management product and is dosed at a slightly higher maximum for that purpose. Ozempic is sometimes prescribed off-label for weight loss, but Wegovy is the on-label choice and the version studied in the STEP weight-loss trials. A licensed clinician determines which — if either — is appropriate for you.

Is Wegovy a higher dose than Ozempic?

Yes. Both are semaglutide, but Wegovy titrates to a higher maximum dose for weight management (2.4 mg/week injectable) than Ozempic's maximum for diabetes (2.0 mg/week).

Does insurance cover Wegovy and Ozempic the same way?

No. Ozempic is widely covered by commercial and Medicare Part D plans for its approved indication (type 2 diabetes). Wegovy is frequently excluded from formularies or requires prior authorization for its weight-management indication. Coverage has improved at some employers but the gap remains wide. Your actual coverage depends on your specific plan.

Is there a cheaper version of semaglutide?

Novo Nordisk's NovoCare savings program brings Wegovy's self-pay cost to approximately $349/month for eligible patients (as of June 2026; verify current eligibility with NovoCare). Some telehealth providers offer compounded semaglutide at lower self-pay rates — but compounded semaglutide is not FDA-approved and is not the same as, or therapeutically equivalent to, Wegovy or Ozempic.

Can I switch from Ozempic to Wegovy for weight loss?

Switching is a clinical decision your prescribing physician makes, depending on your diagnosis, insurance coverage, and response to treatment. It is not something to manage on your own — talk to your provider about the appropriate option for your situation.

Sources & references

1. Ozempic (semaglutide) FDA prescribing information, 2025 — Novo Nordisk; Tier 1
2. Wegovy (semaglutide injection 2.4 mg) FDA prescribing information, 2025 — Novo Nordisk; Tier 1
3. Wilding et al. STEP-1: Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 2021 — primary trial of Wegovy for weight management; Tier 1
4. Lincoff et al. SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM, 2023 — cardiovascular outcomes trial of Wegovy; Tier 1
5. FDA: Human Drug Compounding — regulatory framework for compounded medications; Tier 1
6. FDA: GLP-1 receptor agonist safety and compounding concerns — Tier 1
7. NIDDK: Prescription Medications to Treat Overweight and Obesity — NIH/NIDDK overview; Tier 1
8. FDA approves oral semaglutide (Wegovy pill) for weight loss — AJMC, 2025 — Tier 3 (supporting)
9. Nouri GLP-1 Telehealth Pricing dataset — huggingface.co/datasets/nouriadmin/glp1-telehealth-pricing-2026 (updated 2026)

Medically reviewed by Amber Patel, MD · Nouri Editorial Team · Last reviewed June 29, 2026. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

This article is general education, not medical advice — talk to a licensed clinician about what is right for you. Ozempic®, Wegovy® and Rybelsus® (semaglutide) are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® (tirzepatide) are registered trademarks of Eli Lilly and Company; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Clinical-trial results described in this article are from the FDA-approved branded medications studied in those trials (STEP-1, SELECT, and others); compounded semaglutide and compounded tirzepatide have not been studied in these trials, are not FDA-approved, and are not the same as — or therapeutically equivalent to — the brand-name drugs. GLP-1 medications carry a boxed warning for thyroid C-cell tumors and are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); other risks include pancreatitis, gallbladder disease, and acute kidney injury; these medications are not for use in pregnancy. Individual results vary; no specific weight-loss outcome is guaranteed. Prices are as of June 2026 and change frequently — verify with your pharmacy, insurer, or the manufacturer savings program before making any financial decision.